BIO BIOTON S.A. GPW · Poland

BIOTON (BIO) news

Distress · Aug 4, 2026

Bio-Rad starts restructuring plan with $80 to $90 million in pre-tax charges

Bio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million.

Latest BIOTON news

Feb 13, 2025Distress
Bio-Rad restructuring to cut about 5% of workforce, with $45 million to $50 million in costs
Bio-Rad began the plan on February 7, 2025 and expects it to be substantially completed by the end of fiscal 2025. The company also made a binding offer to buy Stilla Technologies.

Questions about BIOTON

What is the ticker symbol of BIOTON?

BIOTON S.A. trades under the ticker BIO on GPW.

Where is BIOTON listed?

BIOTON S.A. is listed on GPW. Our directory also records these other listings: LS:A0D9SD.

Which country or territory is BIOTON listed under?

Our directory records BIOTON S.A. under Poland.

What does BIOTON do?

Our directory classifies BIOTON S.A. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of BIOTON?

The ISIN recorded for BIOTON S.A. is PLBIOTN00029.

Does aibio.space cover BIOTON?

aibio.space lists BIOTON S.A. among 2,820 public biotech companies and publishes its news here as stories appear.

What is the latest BIOTON (BIO) stock news?

Our latest story on BIOTON, dated Aug 4, 2026: "Bio-Rad starts restructuring plan with $80 to $90 million in pre-tax charges". Bio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million. Source.

Is BIOTON in financial distress?

Our latest distress story, dated Aug 4, 2026: "Bio-Rad starts restructuring plan with $80 to $90 million in pre-tax charges". Bio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million. Source.

Which companies are similar to BIOTON?

Companies in our directory listed in the same country and business area as BIOTON: Celon Pharma SA, Medicofarma Biotech Spolka Akcyjna, Biogened SA, Syn2bio Spolka Akcyjna, Molecure SA, Ryvu Therapeutics SA.

How can I follow BIOTON (BIO) news?

Press Follow on this page to add BIOTON to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming BIOTON so far, in Distress.

Investor discussion: BIOTON

Members talk about BIOTON (BIO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open GPW:BIO on TradingView.

Listing details

BIOTON S.A. is a public biotech or pharmaceutical company listed on GPW under the ticker BIO, recorded under Poland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company: BIOTON S.A.
Ticker: BIO
Listing: GPW
Country or territory: Poland
Business scope: Pharmaceuticals: Major
ISIN: PLBIOTN00029
Other listed symbols: LS:A0D9SD
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction